Quick Answer
RenovoRx, Inc. reported Cash And Cash Equivalents At Carrying Value of $7.02 million for the year ending 2025.
- RenovoRx, Inc. showed a decrease of -1.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from RenovoRx, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), RenovoRx, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 291.3%.
- Historical annual values: Fiscal year 2025: $7.02 million | Fiscal year 2024: $7.15 million | Fiscal year 2023: $1.17 million | Fiscal year 2022: $4.39 million | Fiscal year 2021: $15.19 million | Fiscal year 2020: $1.80 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: